Article

A role for ABCG2 in synergistic interactions between targeted therapies

2026-06-01

Abstract excerpt

<title>Abstract</title> <p>Despite advances in targeted anti-cancer therapy in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC), resistance is still almost inevitable. Identifying combination strategies that can treat drug-resistant tumors effectively is an urgent clinical need. Importantly, accurate mechanistic understanding of these combinations is essential for their optimal clinical development. Here, we aimed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8eebfd42-0544-5ad1-bf8a-f44f30a56541
DOI: 10.21203/rs.3.rs-9858448/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A role for ABCG2 in synergistic interactions between targeted therapiesDOI 10.21203/rs.3.rs-9858448/v1Read

New strategies for targeting drug combinations to overcome mutation-driven drug resistance.Semantic proximity Read

Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapySemantic proximity Read

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing CellsSemantic proximity Read

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.Semantic proximity Read

Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer.Semantic proximity Read

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSemantic proximity Read

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.Semantic proximity Read

Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.Semantic proximity Read

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivoSemantic proximity Read

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.Semantic proximity Read

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.Semantic proximity Read

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read